The Swiss drugmaker is taking on the Chinese biotech's investigational obesity drug, Reuters reports, adding to the rush of big pharma obesity deals.
Recap by typeshit. Full story at Reuters on MSN.
An international food and agribusiness expert links growing interest in fibre to the spread of GLP-1 drugs. Details are thin beyond the claim itself.
Early trial results suggest the shot could one day help people hold onto weight loss after they come off GLP-1 drugs.
Bodybuilder Sam Sulek gives his take on peptides in a short clip from Chris Williamson's show. His views are his own, not medical guidance.
Superpower frames apitegromab's FDA approval as a big step and ties it to concern that GLP-1 users can lose a lot of muscle along with fat.
An investor angle arguing Lilly's triple agonist could become a bigger growth driver than Zepbound, ahead of the company's quarterly report.
A Minutes of Health clip, in English and Arabic, walks through what the GLP-1 hormone does and how popular treatments use it.
Loading…